Jadna B Lopes1, Juliana R Bastos1, Rayssa B Costa1, Daniele C Aguiar1, Fabrício A Moreira2. 1. Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Av. Pres. Antônio Carlos 6627, Belo Horizonte, MG, 31270-901, Brazil. 2. Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Av. Pres. Antônio Carlos 6627, Belo Horizonte, MG, 31270-901, Brazil. fabriciomoreira@icb.ufmg.br.
Abstract
RATIONALE: Cocaine is a psychostimulant drug that facilitates monoaminergic neurotransmission. The endocannabinoid system, comprising the cannabinoid receptors (CB1R and CB2R), the endocannabinoids, and their metabolizing-enzymes, modulates the mesolimbic dopaminergic pathway and represents a potential target for the treatment of addiction. OBJECTIVES: Here, we tested the hypothesis that the cannabinoid receptors are implicated in cocaine-induced motor sensitization, conditioned place preference (CPP), and hippocampal activation. METHODS: Male Swiss mice received injections of AM251 (CB1R antagonist; 0.3-10 mg/kg) or JWH133 (CB2R agonist; 1-10 mg/kg) before acquisition or expression of cocaine (20 mg/kg)-induced sensitization and CPP. After the CPP test, cFos-staining was employed as a marker of neuronal activation in the hippocampus. RESULTS: AM251 inhibited the acquisition (0.3, 1, and 3 mg/kg) and expression (1 and 3 mg/kg) of sensitization, as well as the acquisition (10 mg/kg) of CPP. JWH133 inhibited the acquisition (0.3 and 1 mg/kg) and expression (1 and 3 mg/kg) of both sensitization and CPP. JWH133 effects were reversed by AM630 (CB2R antagonist; 5 mg/kg). AM251 and JWH133 also prevented neuronal activation (c-Fos expression) in the hippocampus of CPP-exposed animals. CONCLUSIONS: CB1R and CB2R have opposite roles in modulating cocaine-induced sensitization and CPP, possibly by preventing neuronal activation in the hippocampus.
RATIONALE: Cocaine is a psychostimulant drug that facilitates monoaminergic neurotransmission. The endocannabinoid system, comprising the cannabinoid receptors (CB1R and CB2R), the endocannabinoids, and their metabolizing-enzymes, modulates the mesolimbic dopaminergic pathway and represents a potential target for the treatment of addiction. OBJECTIVES: Here, we tested the hypothesis that the cannabinoid receptors are implicated in cocaine-induced motor sensitization, conditioned place preference (CPP), and hippocampal activation. METHODS: Male Swiss mice received injections of AM251 (CB1R antagonist; 0.3-10 mg/kg) or JWH133 (CB2R agonist; 1-10 mg/kg) before acquisition or expression of cocaine (20 mg/kg)-induced sensitization and CPP. After the CPP test, cFos-staining was employed as a marker of neuronal activation in the hippocampus. RESULTS:AM251 inhibited the acquisition (0.3, 1, and 3 mg/kg) and expression (1 and 3 mg/kg) of sensitization, as well as the acquisition (10 mg/kg) of CPP. JWH133 inhibited the acquisition (0.3 and 1 mg/kg) and expression (1 and 3 mg/kg) of both sensitization and CPP. JWH133 effects were reversed by AM630 (CB2R antagonist; 5 mg/kg). AM251 and JWH133 also prevented neuronal activation (c-Fos expression) in the hippocampus of CPP-exposed animals. CONCLUSIONS:CB1R and CB2R have opposite roles in modulating cocaine-induced sensitization and CPP, possibly by preventing neuronal activation in the hippocampus.
Entities:
Keywords:
Addiction; Drug abuse; Endocannabinoids; Memory; Psychostimulants; Reward
Authors: Eduardo A V Marinho; Alexandre J Oliveira-Lima; Renan Santos; André W Hollais; Marilia A Baldaia; Raphael Wuo-Silva; Thais S Yokoyama; André L Takatsu-Coleman; Camilla L Patti; Beatriz M Longo; Laís F Berro; Roberto Frussa-Filho Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2014-12-10 Impact factor: 5.067
Authors: M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice Journal: Proc Natl Acad Sci U S A Date: 1990-03 Impact factor: 11.205
Authors: David De Sa Nogueira; Romain Bourdy; Rafael Alcala-Vida; Dominique Filliol; Virginie Andry; Yannick Goumon; Jean Zwiller; Pascal Romieu; Karine Merienne; Mary C Olmstead; Katia Befort Journal: Mol Neurobiol Date: 2022-01-15 Impact factor: 5.590
Authors: Thuy Nguyen; Thomas F Gamage; David B Finlay; Ann M Decker; Tiffany L Langston; Daniel Barrus; Michelle Glass; Jun-Xu Li; Terry P Kenakin; Yanan Zhang Journal: J Med Chem Date: 2021-12-20 Impact factor: 7.446
Authors: Ani Gasparyan; Francisco Navarrete; Marta Rodríguez-Arias; José Miñarro; Jorge Manzanares Journal: Neurotherapeutics Date: 2020-11-23 Impact factor: 7.620
Authors: Isadora L Cortez; Naielly Rodrigues da Silva; Francisco S Guimarães; Felipe V Gomes Journal: Front Psychiatry Date: 2020-10-30 Impact factor: 4.157
Authors: Laila Asth; Lia P Iglesias; Rayssa C Briânis; Anna P Marçal; Nícia P Soares; Daniele C Aguiar; Fabrício A Moreira Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2021-01-20 Impact factor: 3.000
Authors: Maria Carolina Machado da Silva; Giovanni Freitas Gomes; Heliana de Barros Fernandes; Aristóbolo Mendes da Silva; Antônio Lúcio Teixeira; Fabrício A Moreira; Aline Silva de Miranda; Antônio Carlos Pinheiro de Oliveira Journal: Sci Rep Date: 2021-08-06 Impact factor: 4.379